(144 days)
Not Found
No
The summary describes a physical medical device (cervical cage) and its mechanical and biological performance. There is no mention of software, algorithms, or data processing that would indicate the use of AI/ML.
Yes.
The device is indicated for intervertebral body fusion of the spine for the treatment of cervical disc disease, which involves treating a medical condition.
No
The Phusion Metal Cervical Cage is an implantable medical device designed for intervertebral body fusion of the spine. Its purpose is to act as a spacer and hold bone graft to promote fusion, not to diagnose a medical condition.
No
The device description clearly states it is a physical intervertebral fusion device made from porous titanium-nickel material, intended for surgical implantation. It is a hardware device, not software.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Function: The Phusion Metal Cervical Cage is a physical implant designed to be surgically placed in the spine to promote bone fusion. It does not analyze biological samples or provide diagnostic information.
- Intended Use: The intended use clearly states it's for "intervertebral body fusion of the spine" and is a treatment for cervical disc disease. This is a therapeutic and structural function, not a diagnostic one.
The information provided describes a medical device used for surgical implantation, not an in vitro diagnostic test.
N/A
Intended Use / Indications for Use
The Phusion Metal Cervical Cage is indicated for intervertebral body fusion of the spine in skeletally mature patients. The Phusion Metal Cervical Cage is intended for use at one level in the cervical spine, from C3 to C7, for the treatment of cervical disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies). The Phusion Metal Cervical Cage is to be used in patients who have had six weeks of non-operative treatment. Devices are intended to be implanted via an open, anterior approach and used with autogenous bone and supplemental fixation, such as an anterior plating system.
Product codes (comma separated list FDA assigned to the subject device)
ODP
Device Description
The Phusion Metal Cervical Cage is an intervertebral fusion device intended to act as a disc spacer and hold bone graft to promote fusion in the cervical spine. The Phusion Metal Cervical Cage is anatomically shaped with two holes in the anterior end of the device each having a diameter of two millimeters extending to the inner cavity. The Phusion Metal Cervical Cage is manufactured from a porous titanium-nickel (Ti-Ni) intermetallic material. The Phusion Metal Cervical Cage is offered in a variety of shapes and sizes to accommodate variations in patient anatomy. The superior and inferior surfaces of the device has a pattern of teeth to provide increased stability and inhibit movement of the implants. Phusion Metal Cage implants are available in one lordotic configuration of 7 degrees and heights ranging from 5 to 10 mm in 1 mm increments. The Phusion Metal Cage device is single-use only.
Materials: Porous titanium-nickel (Ti-Ni) intermetallic material.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
cervical spine, from C3 to C7
Indicated Patient Age Range
skeletally mature patients
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Characterization of Phusion Metal Cervical Cage devices was performed per the FDA Guidance Document entitled "Class II Special Controls Guidance Document: Intervertebral Body Fusion Device" issued on June 12, 2007. Biomechanical evaluation of the devices was performed per ASTM standards F2077-11, F2267-04, F1714-96, and draft standard F-04.25.02.02. Static and dynamic compressive, shear, and torsion strength of the worst-case devices were measured per ASTM F2077-11. The subsidence characteristics of the worst case device were measured per ASTM F2267-04. Static expulsion testing of the worst-case device for the Phusion Metal Cage and a competitive PEEK device were measured and compared per ASTM draft standard F-04.25.02.02. Collection and characterization of wear debris from dynamic testing was characterized per applicable sections of ASTM F1714-96. Biocompatibility testing of the porous Ti-Ni intermetallic material was performed per ISO 10993 standards.
Bone apposition, ingrowth, spinal fusion, large organs, blood, and serum were evaluated in an ovine model of lumbar spinal fusion of 2 non-contiguous levels (L2-L3 and L4-L5; n = 8 sheep), and sacrifice time points of 4 and 6 months. Blood analysis and serum biochemistry were performed pre-operatively, post-operatively, and weekly up to 6 weeks and monthly thereafter (N=88 total blood samples) through 6 months. The study was performed with commercially available control devices of similar design fabricated from Zeniva PEEK material; both the control and subject devices were implanted with autograft bone harvested from the illac crest. The ovine study was performed per Good Laboratory Practices (GLP) by the Preclinical Surgical Research Laboratory, Colorado State University, USA.
The results of the biomechanical tests showed to Phusion Metal Cages to meet or exceed the strength requirements for cervical spinal devices, and to possess subsidence and expulsion characteristics typical of spinal fusion devices fabricated from permanent polymer or metallic materials. ISO 10993 biocompatibility testing showed the porous Ti-Ni intermetallic Phusion Metal material to be biocompatible and elicit no adverse reactions. Histology, micro-CT, in-life radiography and CT, and biomechanical evaluation of Phusion Metal Cervical Cage devices in the ovine model showed no evidence of adverse tissue reaction, no evidence of migration or pseudoarthrosis, normal bone and soft tissue at the fusion sites, 100% rate of fusion at 6 months (4 sheep, 2 devices/sheep), statistically equivalent fusion at 6 months to the control devices based on bone histology and biomechanical motion, and a statistically significant, higher percentage of bone contact of the superior and inferior surfaces of the devices at 4 and 6 months for the Phusion Metal devices as compared to the PEEK control devices (23.90% vs. 9.94% at 4 months and 56.09% vs. 27.31% at 6 months). Histopathology of the major organs, blood work, ICP-MS of blood, and serum biochemistry showed normal levels of nickel (Ni) with respect to the control PEEK devices and the scientific literature; there was no evidence of abnormal nickel levels for all tissue, blood, and serum samples evaluated in the ovine study.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3080 Intervertebral body fusion device.
(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract image of three faces in profile, stacked on top of each other.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
December 19, 2014
PorOsteon, Incorporated % BioVera. Incorporated Robert A. Poggie, PhD 100 Promenade Saint Louis Notre-Dame-de-L'Ile-Perrot, Quebec, J7V 7P2 Canada
Re: K142041
Trade/Device Name: PorOsteon Phusion Metal Cervical Cage Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: ODP Dated: November 21, 2014 Received: November 25, 2014
Dear Dr. Poggie:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
1
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Mark N. Melkerson -S
Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K142041
Device Name
PorOsteon Phusion Metal Cervical Cage
Indications for Use (Describe)
The Phusion Metal Cervical Cage is indicated for intervertebral body fusion of the spine in skeletally mature patients. The Phusion Metal Cervical Cage is intended for use at one level in the cervical spine, from C3 to C7, for the treatment of cervical disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies). The Phusion Metal Cervical Cage is to be used in patients who have had six weeks of non-operative treatment. Devices are intended to be implanted via an open, anterior approach and used with autogenous bone and supplemental fixation, such as an anterior plating system.
Type of Use (Select one or both, as applicable)
2 Prescription Use (Part 21 CFR 801 Subpart D)
_ Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) SUMMARY
PorOsteon, Inc. – Phusion Metal Cervical Cage
In accordance with 21 CFR 807.92 of the Federal Code of Regulations, the following information is a summary of safety and effectiveness PorOsteon's Phusion Metal Cervical Cage device.
A. SUBMITTERS INFORMATION
| Submitter Name: | BioVera, Inc. |
|---|---|
| Submitter Address: | 65 Promenade Saint-Louis, Notre-Dame-De-L'Ile-Perrot, Quebec, |
| J7V 7P2, CANADA | |
| Contact Person: | Robert A Poggie, PhD |
| Phone Number: | (514) 901-0796; (973) 738-6097 |
| Fax Number: | (514) 901-0796 |
| Date of Submission: | July 22, 2014 |
B. DEVICE IDENTIFICATION & MANUFACTURER
| Manufacturer Name: | PorOsteon, Inc. |
|---|---|
| Manufacturer Address: | 605 Cambridge Ave. Suite B |
| Menlo Park, CA 94025 USA | |
| Registration Number: | TBD |
| Contact Name: | Robert (Bob) Zider |
| Title: | President & CEO |
| Device Trade Name: | PorOsteon Phusion Metal Cervical Cage |
| Device Common Name: | Intervertebral body fusion device |
| Classification Name: | Intervertebral body fusion device - cervical |
| Classification Code: | ODP - Class II |
| Classification Panel: | Orthopedic |
| Regulation Number: | 21 CFR section 888.3080 |
C. PREDICATE DEVICES
K103033 Trabecular Metal Fusion Device; manufactured by Zimmer Trabecular Metal Technology, Inc.
4
D. DEVICE DESCRIPTION
The Phusion Metal Cervical Cage is an intervertebral fusion device intended to act as a disc spacer and hold bone graft to promote fusion in the cervical spine. The Phusion Metal Cervical Cage is anatomically shaped with two holes in the anterior end of the device each having a diameter of two millimeters extending to the inner cavity. The Phusion Metal Cervical Cage is manufactured from a porous titanium-nickel (Ti-Ni) intermetallic material. The Phusion Metal Cervical Cage is offered in a variety of shapes and sizes to accommodate variations in patient anatomy. The superior and inferior surfaces of the device has a pattern of teeth to provide increased stability and inhibit movement of the implants. Phusion Metal Cage implants are available in one lordotic configuration of 7°and heights ranging from 5 to 10 mm in 1 mm increments. The Phusion Metal Cage device is single-use only.
Materials: Porous titanium-nickel (Ti-Ni) intermetallic material.
E. INTENDED USE
The Phusion Metal Cervical Cage is indicated for intervertebral body fusion of the spine in skeletally mature patients. The Phusion Metal Cervical Cage is intended for use at one level in the cervical spine, from C3 to C7, for the treatment of cervical disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies). The Phusion Metal Cervical Cage is to be used in patients who have had six weeks of non-operative treatment. Devices are intended to be implanted via an open, anterior approach and used with autogenous bone and supplemental fixation, such as an anterior plating system.
F. TECHNOLOGICAL CHARACTERISTICS AND SUBSTANTIAL EQUIVALENCE
The subject Phusion Metal Cervical Caqe devices are machined from porous Titanium-Nickel intermetallic bar stock, and are intended for permanent implantation in the cervical spine. Phusion Metal Cervical Cage devices are designed to fit the anatomic profile of the cervical spine. Two size options (depth x width) are available, 12.5 x 14.5 mm and 14.5 x 16.5 mm. All devices are designed with seven (7) degrees of lordosis and are available in height options ranging between 5 and 10 mm in 1 mm increments.
The technological characteristics of PorOsteon Phusion Metal devices are the same as the cited predicate device excepting a change in the porous metal material used to machine the devices and slight variations in geometry. The subject PorOsteon Phusion Metal Cervical Cage devices are machined from porous Titanium-Nickel intermetallic material with nominal porosity of 63% and compressive elastic modulus of 1.0 GPa. The predicate Zimmer Trabecular Metal Fusion devices are machined from porous tantalum material. Both the predicate and subject devices are manufactured from porous metal materials and are indicated for use as an interbody spacer in the cervical spine. The technological characteristics of the PorOsteon Phusion Metal Cervical Cage devices are substantially equivalent to the cited predicate device.
5
G. PERFORMANCE DATA
Characterization of Phusion Metal Cervical Cage devices was performed per the FDA Guidance Document entitled "Class II Special Controls Guidance Document: Intervertebral Body Fusion Device" issued on June 12, 2007. Biomechanical evaluation of the devices was performed per ASTM standards F2077-11, F2267-04, F1714-96, and draft standard F-04.25.02.02. Static and dynamic compressive, shear, and torsion strength of the worst-case devices were measured per ASTM F2077-11. The subsidence characteristics of the worst case device were measured per ASTM F2267-04. Static expulsion testing of the worst-case device for the Phusion Metal Cage and a competitive PEEK device were measured and compared per ASTM draft standard F-04.25.02.02. Collection and characterization of wear debris from dynamic testing was characterized per applicable sections of ASTM F1714-96. Biocompatibility testing of the porous Ti-Ni intermetallic material was performed per ISO 10993 standards.
Bone apposition, ingrowth, spinal fusion, large organs, blood, and serum were evaluated in an ovine model of lumbar spinal fusion of 2 non-contiguous levels (L2-L3 and L4-L5; n = 8 sheep), and sacrifice time points of 4 and 6 months. Blood analysis and serum biochemistry were performed pre-operatively, post-operatively, and weekly up to 6 weeks and monthly thereafter (N=88 total blood samples) through 6 months. The study was performed with commercially available control devices of similar design fabricated from Zeniva PEEK material; both the control and subject devices were implanted with autograft bone harvested from the illac crest. The ovine study was performed per Good Laboratory Practices (GLP) by the Preclinical Surgical Research Laboratory, Colorado State University, USA.
The results of the biomechanical tests showed to Phusion Metal Cages to meet or exceed the strength requirements for cervical spinal devices, and to possess subsidence and expulsion characteristics typical of spinal fusion devices fabricated from permanent polymer or metallic materials. ISO 10993 biocompatibility testing showed the porous Ti-Ni intermetallic Phusion Metal material to be biocompatible and elicit no adverse reactions. Histology, micro-CT, in-life radiography and CT, and biomechanical evaluation of Phusion Metal Cervical Cage devices in the ovine model showed no evidence of adverse tissue reaction, no evidence of migration or pseudoarthrosis, normal bone and soft tissue at the fusion sites, 100% rate of fusion at 6 months (4 sheep, 2 devices/sheep), statistically equivalent fusion at 6 months to the control devices based on bone histology and biomechanical motion, and a statistically significant, higher percentage of bone contact of the superior and inferior surfaces of the devices at 4 and 6 months for the Phusion Metal devices as compared to the PEEK control devices (23.90% vs. 9.94% at 4 months and 56.09% vs. 27.31% at 6 months). Histopathology of the major organs, blood work, ICP-MS of blood, and serum biochemistry showed normal levels of nickel (Ni) with respect to the control PEEK devices and the scientific literature; there was no evidence of abnormal nickel levels for all tissue, blood, and serum samples evaluated in the ovine study.
H. CONCLUSION
The PorOsteon Phusion Metal Cervical Cage system is substantially equivalent to the predicate device, the Zimmer Trabecular Metal Fusion Device.